Body fluid levels of neuroactive amino acids in autism spectrum disorders: a review of the literature
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
A review of studies on the body fluid levels of neuroactive amino acids, including glutamate, glutamine, taurine, gamma-aminobutyric acid (GABA), glycine, tryptophan, D-serine, and others, in autism spectrum disorders (ASD) is given. The results reported in the literature are generally inconclusive and contradictory, but there has been considerable variation among the previous studies in terms of factors such as age, gender, number of subjects, intelligence quotient, and psychoactive medication being taken. Future studies should include simultaneous analyses of a large number of amino acids [including D-serine and branched-chain amino acids (BCAAs)] and standardization of the factors mentioned above. It may also be appropriate to use saliva sampling to detect amino acids in ASD patients in the future-this is noninvasive testing that can be done easily more frequently than other sampling, thus providing more dynamic monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model of autism: increased ratio of excitation/inhibition in key neural systems
Rubenstein, J. L. R., & Merzenich, M. M. (2003) · Genes, Brain and Behavior · doi:10.1034/j.1601-183x.2003.00037.x · Cited by 2,768 · cited 1×
“Reduced GABAergic action in human and animal models of ASD has been proposed to be one of the reasons for an imbalance between excitation and inhibition (Rubenstein and Merzenich 2003; Gogolla et al. 2009; Blatt and Fatemi 2011; Ito 2016; Robertson et al. 2016).”
BackgroundJames, S. J., Cutler, P., Melnyk, S., Jernigan, S., Janak, L., Gaylor, D. W., & Neubrander, J. A. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.6.1611 · Cited by 955
Prevalence of autism-spectrum conditions: UK school-based population study
Baron-Cohen, S., Scott, F. J., Allison, C., Williams, J., Bolton, P., Matthews, F. E., & Brayne, C. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.059345 · Cited by 918
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 2×
“, schizophrenia and mood disorders) that have symptoms, such as cognitive impairment and problems with social interactions, in common with ASD (Coyle 2006; Grant et al. 2006; Lam et al. 2006; Labrie et al. 2008; Ongür et al. 2008; Yüksel and Öngür 2010; Durrant and Heresco-Levy 2014).”
BackgroundCommon circuit defect of excitatory-inhibitory balance in mouse models of autism
Gogolla, N., LeBlanc, J. J., Quast, K. B., Südhof, T. C., Fagiolini, M., & Hensch, T. K. (2009) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-009-9023-x · Cited by 610 · cited 1×
“Reduced GABAergic action in human and animal models of ASD has been proposed to be one of the reasons for an imbalance between excitation and inhibition (Rubenstein and Merzenich 2003; Gogolla et al. 2009; Blatt and Fatemi 2011; Ito 2016; Robertson et al. 2016).”
BackgroundOxytocin-Mediated GABA Inhibition During Delivery Attenuates Autism Pathogenesis in Rodent Offspring
Tyzio, R., Nardou, R., Ferrari, D. C., Tsintsadze, T., Shahrokhi, A., Eftekhari, S., Khalilov, I., Tsintsadze, V., Brouchoud, C., Chazal, G., et al. (2014) · Science · doi:10.1126/science.1247190 · Cited by 601 · cited 2×
“They shift from excitatory to inhibitory neurotransmitters at birth and in maturation, and if that does not happen it may result in neurological disorders, including ASD (Tyzio et al. 2006, 2014).”
BackgroundYamada, J., Okabe, A., Toyoda, H., Kilb, W., Luhmann, H. J., & Fukuda, A. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.062471 · Cited by 572 · cited 3×
“…and neurological disorders, such as schizophrenia (Labrie et al. 2008; Nunes et al. 2012; Balu and Coyle 2015; Ozeki et al. 2016), bipolar 1 3 disorder (Yamada et al. 2004; Young and Barrett 2015), depression (Hashimoto et al. 2015, 2016; Deutschenbaur et al. 2016), Alzheimer’s disease (Paula-Lima…”
BackgroundThe serotonin system in autism spectrum disorder: From biomarker to animal models
Muller, C. L., Anacker, A. M. J., & Veenstra-VanderWeele, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.010 · Cited by 531 · cited 3×
“…in several excellent review articles (Lam et al. 2006; Pardo and Eberhart 2007; Aoki et al. 2012; Parellada et al. 2014; Lozano et al. 2015; Rozas et al. 2015; Subramanian et al. 2015; Zhang et al. 2015; Martin et al. 2016; Muller et al. 2016; Park et al. 2016); this review focuses on amino acids.”
BackgroundBranched-Chain Amino Acids and Brain Function
Fernstrom, J. D. (2005) · The Journal of Nutrition · doi:10.1093/jn/135.6.1539s · Cited by 514 · cited 2×
“Leucine, isoleucine, and valine are all termed branched-chain amino acids (BCAAs) and share a transport system with large, neutral amino acids (LNAAs), such as tryptophan, tyrosine, and phenylalanine which are the precursors of the neurotransmitter amines 5-hydroxytryptamine (5-HT, serotonin) and the catecholamines (F…”
BackgroundPardo, C. A., & Eberhart, C. G. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00102.x · Cited by 514
The diagnosis of autism and Asperger syndrome: findings from a survey of 770 families
Howlin, P., & Asgharian, A. (1999) · Developmental Medicine & Child Neurology · doi:10.1017/s0012162299001656 · Cited by 500
Fatemi, S. H., Halt, A. R., Stary, J. M., Kanodia, R., Schulz, S. C., & Realmuto, G. R. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01430-0 · Cited by 500
Reduced GABAergic Action in the Autistic Brain
Robertson, C. E., Ratai, E.-M., & Kanwisher, N. (2016) · Current Biology · doi:10.1016/j.cub.2015.11.019 · Cited by 327
Neurochemical correlates of autistic disorder: a review of the literature
Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2005.03.003 · Cited by 318 · cited 5×
“…(e.g., schizophrenia and mood disorders) that have symptoms, such as cognitive impairment and problems with social interactions, in common with ASD (Coyle 2006; Grant et al. 2006; Lam et al. 2006; Labrie et al. 2008; Ongür et al. 2008; Yüksel and Öngür 2010; Durrant and Heresco-Levy 2014).”
BackgroundInfluentialEffects of tryptophan depletion in drug-free adults with autistic disorder
McDougle, C. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110029004 · Cited by 301
Gaetz, W., Bloy, L., Wang, D. J., Port, R. G., Blaskey, L., Levy, S. E., & Roberts, T. P. L. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2013.05.068 · Cited by 267 · cited 2×
“Neuroimaging techniques reported decreased GABA in brains of ASD patients (Kubas et al. 2012; Gaetz et al. 2014; Rojas et al. 2014; Omura et al. 2015; Cochran et al. 2015).”
BackgroundMetabolic Perturbance in Autism Spectrum Disorders: A Metabolomics Study
Ming, X., Stein, T. P., Barnes, V., Rhodes, N., & Guo, L. (2012) · Journal of Proteome Research · doi:10.1021/pr300910n · Cited by 234
The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond
Balu, D. T., & Coyle, J. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.12.004 · Cited by 208 · cited 2×
“…possibly involved in the pathogenesis of several psychiatric and neurological disorders, such as schizophrenia (Labrie et al. 2008; Nunes et al. 2012; Balu and Coyle 2015; Ozeki et al. 2016), bipolar 1 3 disorder (Yamada et al. 2004; Young and Barrett 2015), depression (Hashimoto et al. 2015,…”
BackgroundYoung, L. J., & Barrett, C. E. (2015) · Science · doi:10.1126/science.aaa8120 · Cited by 200 · cited 3×
“…such as schizophrenia (Labrie et al. 2008; Nunes et al. 2012; Balu and Coyle 2015; Ozeki et al. 2016), bipolar 1 3 disorder (Yamada et al. 2004; Young and Barrett 2015), depression (Hashimoto et al. 2015, 2016; Deutschenbaur et al. 2016), Alzheimer’s disease (Paula-Lima et al. 2013;…”
BackgroundAlteration of Plasma Glutamate and Glutamine Levels in Children with High-Functioning Autism
Shimmura, C., Suda, S., Tsuchiya, K. J., Hashimoto, K., Ohno, K., Matsuzaki, H., Iwata, K., Matsumoto, K., Wakuda, T., Kameno, Y., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025340 · Cited by 189 · cited 10×
“…controls (HCs) are contradictory, with some reporting increased levels (Moreno-Fuenmayor et al. 1996; Aldred et al. 2003; MacDermot et al. 2005; Shimmura et al. 2011; Tirouvanziam et al. 2011; Naushad et al. 2013; El-Ansary and Al-Ayadhi 2014; Cai et al. 2016) and some decreased levels…”
BackgroundResultInfluentialPlasma amino acid levels in children with autism and their families
Aldred, S., Moore, K. M., Fitzgerald, M., & Waring, R. H. (2003) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1022238706604 · Cited by 188 · cited 10×
“…Hassan et al. 2013) Decreased (van Elst et al. 2014) No difference (Cochran et al. 2015) Glutamine Plasma Decreased (Moreno-Fuenmayor et al. 1996; Aldred et al. 2003; Shimmura et al. 2011; Tirouvanziam et al. 2011; Good 2011a; Tu et al. 2012; El-Ansary 2016) Serum No difference (Shinohe et al.…”
BackgroundResultInfluentialDeregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
Paula‐Lima, A. C., Brito‐Moreira, J., & Ferreira, S. T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12304 · Cited by 170 · cited 2×
“…Ozeki et al. 2016), bipolar 1 3 disorder (Yamada et al. 2004; Young and Barrett 2015), depression (Hashimoto et al. 2015, 2016; Deutschenbaur et al. 2016), Alzheimer’s disease (Paula-Lima et al. 2013; Madeira et al. 2015), and addiction (D’Ascenzo et al. 2014; Seif et al. 2015; Liu et al. 2016).”
BackgroundZwaigenbaum, L., Bryson, S. E., Brian, J., Smith, I. M., Roberts, W., Szatmari, P., Roncadin, C., Garon, N., & Vaillancourt, T. (2016) · Autism Research · doi:10.1002/aur.1585 · Cited by 165 · cited 1×
“Receiving diagnosis at an early stage of development could contribute to the early intervention and therapy, benefiting both patients and their families (Zwaigenbaum et al. 2015; Sacrey et al. 2015; Brian et al. 2015).”
BackgroundPaşca, S. P., Nemeş, B., Vlase, L., Gagyi, C. E., Dronca, E., Miu, A. C., & Dronca, M. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.09.040 · Cited by 151 · cited 3×
“…showed that homocysteine levels were increased in ASD patients compared with HCs: Tu et al. (2012) reported levels in plasma, Ali et al. (2011) and Paşca et al. (2006) reported levels in serum, and Noto et al. (2014) and Puig-Alcaraz et al. (2015) reported levels in urine samples, and all were…”
BackgroundResultYang, C.-J., Tan, H.-P., & Du, Y.-J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.021 · Cited by 132
Naaijen, J., Lythgoe, D. J., Amiri, H., Buitelaar, J. K., & Glennon, J. C. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.02.009 · Cited by 117
Hashimoto, K., Bruno, D., Nierenberg, J., Marmar, C. R., Zetterberg, H., Blennow, K., & Pomara, N. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.8 · Cited by 90
D-Serine and D-Cycloserine Reduce Compulsive Alcohol Intake in Rats
Seif, T., Simms, J. A., Lei, K., Wegner, S., Bonci, A., Messing, R. O., & Hopf, F. W. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.84 · Cited by 75 · cited 1×
“…Ozeki et al. 2016), bipolar 1 3 disorder (Yamada et al. 2004; Young and Barrett 2015), depression (Hashimoto et al. 2015, 2016; Deutschenbaur et al. 2016), Alzheimer’s disease (Paula-Lima et al. 2013; Madeira et al. 2015), and addiction (D’Ascenzo et al. 2014; Seif et al. 2015; Liu et al. 2016).”
Metabolite alterations in autistic children: a 1H MR spectroscopy study
Kubas, B., Kułak, W., Sobaniec, W., Tarasow, E., Łebkowska, U., & Walecki, J. (2012) · Advances in Medical Sciences · doi:10.2478/v10039-012-0014-x · Cited by 74 · cited 6×
“Kuwabara et al. (2013) showed elevated plasma TAUR levels in adults with ASD and proposed that TAUR is compensatory against pathogenesis of ASD, such as that caused by oxidative stress.”
BackgroundInfluentialAltered amino acid excretion in children with autism
Evans, C., Dunstan, H. R., Rothkirch, T., Roberts, T. K., Reichelt, K. L., Cosford, R., Deed, G., Ellis, L. B., & Sparkes, D. L. (2008) · Nutritional Neuroscience · doi:10.1179/147683008x301360 · Cited by 71 · cited 15×
“…with HCs, GLY levels in plasma (Tirouvanziam et al. 2011) and serum (Shinohe et al. 2006) of ASD subjects have been reported to be unchanged, and levels in urine samples reported to be increased (Nadal-Desbarats et al. 2014; Noto et al. 2014) or decreased (Evans et al. 2008; Ming et al. 2012).”
BackgroundInfluentialLiu, Z.-Q., Gu, X.-H., Yang, Y.-J., Yin, X.-P., Xu, L.-J., & Wang, W. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.02.002 · Cited by 23 · cited 2×
“…etiology of ASD, fragile X syndrome, and tuberous sclerosis complex (TSC), but most of these studies have focused on glutamate, GABA, and/or glutamine (El-Ansary and Al-Ayadhi 2014; Rojas 2014; Santini et al. 2014; Rozas et al. 2015; Cochran et al. 2015; Lozano et al. 2015; Robertson et al. 2016).”
BackgroundSelf-citation
Cited by
Iglesias-Vázquez, L., Van Ginkel Riba, G., Arija, V., & Canals, J. (2020) · Nutrients · doi:10.3390/nu12030792 · Cited by 352
“Meanwhile, lower levels of glutathione, homocysteine, methionine, and S-adenosylmethionine have been observed more in ASD children than in neurotypical children [66,67].”
BackgroundThe Gut-Immune-Brain Axis in Autism Spectrum Disorders; A Focus on Amino Acids
van Sadelhoff, J. H. J., Perez Pardo, P., Wu, J., Garssen, J., van Bergenhenegouwen, J., Hogenkamp, A., Hartog, A., & Kraneveld, A. D. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00247 · Cited by 71
Pan, S., Wei, H., Yuan, S., Kong, Y., Yang, H., Zhang, Y., Cui, X., Chen, W., Liu, J., & Zhang, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1022879 · Cited by 51
Serum amino acid spectrum in children with autism spectrum disorder (ASD)
Skalny, A. V., Skalny, A. A., Lobanova, Y. N., Korobeinikova, T. V., Ajsuvakova, O. P., Notova, S. V., Burtseva, T. I., Skalnaya, M. G., & Tinkov, A. A. (2020) · Research in Autism Spectrum Disorders · doi:10.1016/j.rasd.2020.101605 · Cited by 16
Metadata
- Authors
- Zheng, H.-F., Wang, W.-Q., Li, X.-M., Rauw, G., & Baker, G. B.
- Venue
- Amino Acids
- Published
- 2016-09-29
- Volume
- 49
- Issue
- 1
- Pages
- 57-65
- ISSN
- 0939-4451 (ISSN-L)
- 1438-2199
- OpenAlex
- W2526758247
- Cited by
- 82
- References
- 31
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.